| Autor: |
Tatiana do Nascimento Pedrosa, Ester Cerdeira Sabino, Emily Figueiredo Neves Yuki, Rosa Maria Rodrigues Pereira, Eloisa Bonfa, Nadia E. Aikawa, Carolina Torres Ribeiro, Percival D. Sampaio-Barros, Carla G. S. Saad, Ana Cristina Medeiros-Ribeiro, Solange R. G. Fusco, Alberto José da Silva Duarte, Giordano B. H. Deveza, Sandra Gofinet Pasoto, Clovis A. Silva, Leila Antonangelo, Marta Heloísa Lopes, Esper G. Kallas, Priscila T Rojo, Danieli Andrade, Victor Adriano de Oliveira Martins, Samuel Katsuyuki Shinjo |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Web of Science |
| DOI: |
10.21203/rs.3.rs-551982/v1 |
| Popis: |
CoronaVac(SARS-CoV-2 inactivated vaccine) has been largely used as the main immunogen for COVID-19 in several countries. However, its immunogenicity in immunocompromised individuals has not been established. This was a prospective controlled study of 910 adult ARD patients and 182 age- and sex-matched control group(CG) who received two doses of CoronaVac in a 28-days interrval. Anti-SARS-Cov-2 IgG and neutralizing antibodies were assessed at each vaccine shot and 6 weeks after the 2nd dose. Vaccine adverse events(AE) were similar in both groups. We observed significant lower anti-SARS-Cov-2 IgG seroconversion(70.4% vs. 95.5%,p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
